Overview

Dose-Finding Study of PDC31 in Patients With Primary Dysmenorrhea

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine a safe and effective dose range for intravenous administration (infusion) of PDC31 by determining the maximum tolerated dose of PDC31 in patients with primary dysmenorrhea.
Phase:
Phase 1
Details
Lead Sponsor:
PDC Biotech GmbH